Proof-of-principle that the PI3K pathway in cancer can be successfully targeted has been demonstrated by the development of rapamycin analogs that inhibit mTORC1 kinase (e.g., temsirolimus and everolimus) [100]. This evidence concerns the gene PIK3CB and cancer.